Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Crelux blackdogvfx

News and Trends 30 Nov 2017

Interview: Why Asian CROs are Turning to the European Biotech Market

The demand for contract research organizations (CROs) has been increasing steadily worldwide. With more and more clinical development programs being launched and a heightened demand for pharmaceutical products, companies in the biotechnology, pharmaceutical and medical technology industries are frequently deciding to outsource R&D processes to CROs. To give you an idea in numbers: In 2014, […]

November 30, 2017 - 11 minutesmins - By External Contributor

Biomillenia Qiagen microbiome chip 1

News and Trends 30 Nov 2017

Qiagen Joins French Biotech to Build the Next Generation of Microbiome Technology

Biomillenia harnesses the power of bacteria to keep the body healthy. The biotech has joined forces with Qiagen to develop microbiome-on-a-chip technology. Scientists around the world believe that the microbiome could hold the key to human health. One company in this area, Biomillenia, develops microbial strains from previously unculturable microbiomes to unlock its full potential. The company has now […]

November 30, 2017 - 3 minutesmins - By Alex Dale

erik Wiklund

Inside Labiotech 30 Nov 2017

Why is Erik Digman Wiklund, CFO of Targovax, reading Labiotech.eu?

Leaders & Readers: I had a chat with Erik Digman Wiklund about why he reads Labiotech.eu. He is the CFO of Targovax, a clinical-stage company focusing on the development of immuno-oncology therapies. This interview has just been lightly edited for grammar. Why do you read Labiotech.eu? I enjoy the easygoing and fun style of Labiotech, which […]

November 30, 2017 - 2 minutesmins - By Katherine Douglas

dystrophic epidermolysis bullosa proqr rna therapy

News and Trends 30 Nov 2017

RNA Therapy for Rare Skin Disease Gets Orphan Status

The EMA has granted orphan drug designation to ProQR’s QR-313, a possible first disease-modifying treatment for the rare disease dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa (DEB) is a genetic disease that causes the skin to easily blister, severely affecting the quality of life of patients since a very early age. Current treatment is limited to […]

November 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biotech investment pharma innovation5

In Depth 30 Nov 2017

Will Pharma Reach a Negative Return on its R&D Investments?

It isn’t news that pharma’s business model is in trouble, but a new report from Evaluate and number crunching from Endpoints show the size of the problem. Pharma depends on innovation, which is why it turns to biotech as the powerhouse of novel technologies. About 65% of recently drugs come from small life sciences companies […]

November 30, 2017 - 3 minutesmins - By Evelyn Warner

Downs syndrome cause switzlerland2 1

News and Trends 29 Nov 2017

What Exactly Happens in the Cells of People with Down’s Syndrome?

Researchers in Switzerland have taken a closer look at the cells of Down’s syndrome patients, with widespread changes in protein expression observed. Down’s syndrome, or trisomy 21, is the most common genetic disease, characterized by facial dysmorphism, learning disabilities, poor muscle tone and heart problems. Research carried out at the University of Geneva and ETH […]

November 29, 2017 - 3 minutesmins - By Alex Dale

ADVERTISEMENT

Biocartis infection cancer test

News and Trends 29 Nov 2017

Belgian Firm Raises €80M for Rapid Infection and Cancer Tests

Biocartis is aiming to raise funds through a private placement of shares in order to support sales and further development of its rapid cancer tests. Based in Mechelen, Belgium, Biocartis focuses on developing fast, easy-to-use diagnostics. In order to boost its molecular diagnostics technology, the company launched a private equity placement of shares on Euronext […]

November 29, 2017 - 1 minutemin - By Clara Rodríguez Fernández

merck pfizer avelumab gastric cancer

News and Trends 29 Nov 2017

Merck and Pfizer’s Checkpoint Inhibitor Fails to Treat Gastric Cancer

Avelumab, marketed as Bavencio by Pfizer and Merck, has failed to show better efficacy than chemotherapy in a Phase III trial with gastric cancer patients. Merck (the German one) and Pfizer joined the checkpoint inhibitor club earlier this year with the approval of Bavencio (avelumab) in both the US and Europe. Looking to keep expanding the […]

November 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Global bioenergies loréal isobutene 1

News and Trends 29 Nov 2017

Guilt-free and Odour-free: French Biotech Fights for Green Cosmetics

Global Bioenergies has produced the first batch of its sustainable isobutene, which L’Oréal will use to produce environmentally friendly hairspray and deodorant. Global Bioenergies has produced the first batch of its sustainable biochemical for L’Oréal. The French biotech hopes to support the shift away from fossil fuels that could change the world. It has taken its first step […]

November 29, 2017 - 3 minutesmins - By Alex Dale

7 Trianni Rudmer Zwerver4

News and Trends 29 Nov 2017

One Mouse with All-Human Antibodies

Monoclonal antibodies have long been the focus of research surrounding drug development against inflammatory diseases and cancer. For decades, researchers have had to travel along a strenuous path to get to where we are now. After monoclonal antibodies (mAb) were discovered in the first half of the 20th century, researchers quickly understood that animals, such […]

November 29, 2017 - 6 minutesmins - By External Contributor

Portugal Ventures Ricardo Perdigao Henriques

Interview 29 Nov 2017

What’s Going on in the Biotech Ecosystem of Portugal?

The biotech ecosystem in Portugal is rapidly growing. Ricardo Perdigao, Investment Manager at Portugal Ventures, discusses the country’s potential in this field. Portugal has seen the number of life sciences startups triple between 2008 to 2015. A study by Portugal Ventures links this growth to a better funding environment and to researchers being more aware that […]

November 29, 2017 - 3 minutesmins - By External Contributor

auris medical sudden deafness

News and Trends 28 Nov 2017

A Treatment for Sudden Deafness Fails in Phase III

Auris Medical’s treatment for sudden deafness has failed to meet its efficacy endpoint, leading the company to terminate a second trial early. Based in Zug, Switzerland, Auris Medical is developing what could be the first treatments for inner ear disorders such as hearing loss, tinnitus, and vertigo. But today, the company suffered a setback. Its lead […]

November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT